The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | How to sequence therapies in CLL after venetoclax discontinuation?
Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the rationale and results of an international retrospective cohort study of the efficacy of therapies following venetoclax discontinuation in chronic lymphocytic leukemia (CLL). Dr Mato highlights that the therapies they were most interested in included bruton tyrosine kinase inhibitors, phosphoinositide 3-kinase inhibitors and cellular therapy (CAR-T or allo-HSCT). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
